Flywire to Announce Third Quarter 2022 Results on November 8, 2022
Get Alerts FLYW Hot Sheet
Join SI Premium – FREE
BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Today, Flywire Corporation (Nasdaq: FLYW) (Flywire), a global payments enablement and software company, announced that its third quarter 2022 financial results will be released after market close on Tuesday, November 8, 2022. Flywire will host a conference call to discuss its third quarter 2022 financial results at 5:00pm ET the same day. Hosting the call will be Mike Massaro, CEO, Rob Orgel, President and COO, and Mike Ellis, CFO.
The conference call will be webcast live from Flywire’s investor relations website at https://ir.flywire.com/. A replay will be available on the investor relations website following the call.
About Flywire
Flywire is a global payments enablement and software company. We combine our proprietary global payments network, next-gen payments platform and vertical-specific software to deliver the most important and complex payments for our clients and their customers.
Flywire leverages its vertical-specific software and payments technology to deeply embed within the existing A/R workflows for its clients across the education, healthcare and travel vertical markets, as well as in key B2B industries. Flywire also integrates with leading ERP systems, such as NetSuite, so organizations can optimize the payment experience for their customers while eliminating operational challenges.
Flywire supports more than 2,800 clients with diverse payment methods in more than 140 currencies across 240 countries and territories around the world. The company is headquartered in Boston, MA, USA with global offices. For more information, visit www.flywire.com. Follow Flywire on Twitter, LinkedIn and Facebook.
Contacts
Investor Relations:ICR[email protected]
Media:Sarah King[email protected]
Prosek Partners[email protected]
Source: Flywire Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
- Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study
- 7 Best Cryptos in 2026 to Watch: Apeing’s Crypto Presale Making Headlines With Over $80K Raised
Create E-mail Alert Related Categories
Globe Newswire, Press ReleasesRelated Entities
Twitter, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share